$SMPL

Simply Good Foods: Fiscal Q3 Earnings Snapshot

Simply Good Foods (SMPL) reported a fiscal Q3 loss of $52 million, or 58 cents per share. Adjusted earnings were 42 cents per share, above Zacks’ estimate of 35 cents. Revenue was $357 million, above the $331.3 million forecast. For the quarter ending August, it expects $322 million to $332 million revenue, and full-year revenue of $1.35 billion to $1.36 billion.

Original reporting
Published Jul 9, 2026, 12:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 9, 2026, 1:07 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Simply Good Foods: Fiscal Q3 Earnings Snapshot — source image
Decision brief

The 30-second read

$SMPLBullishMed
01

Why it matters

The key tradable inputs are the EPS and revenue beats versus consensus and the company’s stated revenue ranges for the current quarter and full year.

02

Market read

Q3 adjusted EPS and revenue beat consensus, and management issued revenue guidance for the quarter ending August and full-year range.

03

What to watch

The article omits cash flow, gross margin, and segment performance; traders may discount the beat if underlying profitability metrics were weak.

Relevance 8/10Novelty 7/10Timing: after-hours/Thursday earnings release for fiscal Q3 and guidance for quarter ending August

Background

AP reports Simply Good Foods fiscal third-quarter results, including adjusted EPS, revenue, and forward revenue guidance.

Company-level read

Ticker impact

$SMPLBullishMedium confidence
Context

Simply Good Foods reported fiscal Q3 loss of $0.58 per share and adjusted EPS of $0.42, beating analyst estimates, plus revenue and guidance.

Expected impact

Likely supportive near-term sentiment versus consensus, with follow-through depending on how investors weigh guidance ranges.

Evidence & confidence

The article provides concrete EPS, revenue, and both quarter and full-year revenue guidance that can re-anchor expectations.

Market effects

Nutritional foods peers may see modest read-across if investors treat the beat and guidance as evidence of demand stability.

Limited, as the disclosure is company-specific with no broader regional macro/regulatory catalyst.

Low, since the article contains no international expansion, supply-chain, or commodity-linked driver.

Counterpoint

A single-quarter beat may not change the longer-term thesis if margins, cash flow, or demand trends are deteriorating, which are not discussed here.

Key entities

  • Simply Good Foods Co.

    Nutritional foods company reporting fiscal Q3 results and revenue guidance.

  • Zacks Investment Research

    Provides analyst estimate benchmarks cited in the article.

Related articles

$UTZMed

Family-owned companies have big appetites for US snack M&A

Utz UTZ.N agreed to be taken private by Germany’s Intersnack Group, with Utz’s founding families, in a deal valued at nearly $3 billion, the first U.S. acquisition for Intersnack. The article cites other family-led snack deals including Ferrero’s purchases of WK Kellogg and Power Crunch, and Mars’s $36 billion take-private of Kellanova. It notes valuation multiples and potential targets.

$SMPLMedAI 8/10

Simply Good Foods Beats Q3 Estimates, But 'Under-Shipping' Plan Points To Softer Q4 - Simply Good Foods (

Simply Good Foods (NASDAQ:SMPL) reported fiscal Q3 results that beat expectations, helped by better performance at Quest and OWYN. DA Davidson said Q4 guidance implies the company will “under-ship relative to consumption,” pointing to softer demand. Analyst Matt Curtis kept a Neutral rating and cut the price target to $14. Management raised FY revenue guidance to $1.345-$1.355B and adjusted EBITDA to $220-$225M.

$METAMed

Futures Rise, Oil Drops As Markets Ignore Latest Middle East Airstrikes

US stock index futures rose in premarket while oil fell after a second day of US strikes on Iranian targets and Tehran retaliation against Gulf allies. S&P 500 futures were up 0.2% and Nasdaq 100 up 0.6%. AstraZeneca shares dropped 9% in London after Wainua failed in a late-stage trial; Ionis fell 19%. SK Hynix ADR demand was strong; Ceco Environmental rose after JPMorgan coverage.